Impact of Losing HRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2020 Jul 8

PMID 32631902

Citations 16

Authors

Vasty Osei-Amponsa

Vinidhra Sridharan

Mayank Tandon

Christine N Evans

Kimberly Klarmann

Kwong Tai Cheng

Justin Lack

Raj Chari

Kylie J Walters

Affiliations

Soon will be listed here.

Abstract

hRpn13/ADRM1 links substrate recruitment with deubiquitination at the proteasome through its proteasome- and ubiquitin-binding Pru domain and DEUBAD domain, which binds and activates deubiquitinating enzyme (DUB) UCHL5/Uch37. Here, we edit the HCT116 colorectal cancer cell line to delete part of the hRpn13 Pru, producing cells that express truncated hRpn13 (trRpn13), which is competent for UCHL5 binding but defective for proteasome interaction. cells demonstrate reduced levels of proteasome-bound ubiquitinated proteins, indicating that the loss of hRpn13 function at proteasomes cannot be fully compensated for by the two other dedicated substrate receptors (hRpn1 and hRpn10). Previous studies indicated that the loss of full-length hRpn13 causes a corresponding reduction of UCHL5. We find UCHL5 levels unaltered in cells, but hRpn11 is elevated in and cells, perhaps from cell stress. Despite the ∼90 DUBs in human cells, including two others in addition to UCHL5 at the proteasome, we found deletion of UCHL5 from HCT116 cells to cause increased levels of ubiquitinated proteins in whole-cell extract and at proteasomes, suggesting that UCHL5 activity cannot be fully assumed by other DUBs. We also report anticancer molecule RA190, which binds covalently to hRpn13 and UCHL5, to require hRpn13 Pru and not UCHL5 for cytotoxicity.

Citing Articles

Potential roles of UCH family deubiquitinases in tumorigenesis and chemical inhibitors developed against them.

Xu Z, Zhang N, Shi L Am J Cancer Res. 2024; 14(6):2666-2694.

PMID: 39005671 PMC: 11236784. DOI: 10.62347/OEGE2648.

Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer.

Anchoori R, Tseng S, Tsai H, Palande V, Rudek M, Roden R PLoS One. 2024; 19(7):e0305710.

PMID: 38990850 PMC: 11239005. DOI: 10.1371/journal.pone.0305710.

A structure-based designed small molecule depletes hRpn13 and a select group of KEN box proteins.

Lu X, Chandravanshi M, Sabbasani V, Gaikwad S, Hughitt V, Gyabaah-Kessie N Nat Commun. 2024; 15(1):2485.

PMID: 38509117 PMC: 10954691. DOI: 10.1038/s41467-024-46644-7.

hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4, and transcription factor NF-κB p50.

Osei-Amponsa V, Chandravanshi M, Lu X, Magidson V, Das S, Andresson T Mol Cell. 2023; 84(3):522-537.e8.

PMID: 38151017 PMC: 10872465. DOI: 10.1016/j.molcel.2023.11.035.

The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer.

Tychhon B, Allen J, Gonzalez M, Olivas I, Solecki J, Keivan M Front Med (Lausanne). 2023; 10:1209425.

PMID: 37502358 PMC: 10371016. DOI: 10.3389/fmed.2023.1209425.

References

Hamazaki J, Iemura S, Natsume T, Yashiroda H, Tanaka K, Murata S . A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes. EMBO J. 2006; 25(19):4524-36. PMC: 1589993. DOI: 10.1038/sj.emboj.7601338. View

Al-Shami A, Jhaver K, Vogel P, Wilkins C, Humphries J, Davis J . Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development. PLoS One. 2010; 5(10):e13654. PMC: 2965108. DOI: 10.1371/journal.pone.0013654. View

Harrow J, Frankish A, Gonzalez J, Tapanari E, Diekhans M, Kokocinski F . GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012; 22(9):1760-74. PMC: 3431492. DOI: 10.1101/gr.135350.111. View

Young P, Deveraux Q, Beal R, Pickart C, Rechsteiner M . Characterization of two polyubiquitin binding sites in the 26 S protease subunit 5a. J Biol Chem. 1998; 273(10):5461-7. DOI: 10.1074/jbc.273.10.5461. View

Qiu X, Ouyang S, Li C, Miao S, Wang L, Goldberg A . hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37. EMBO J. 2006; 25(24):5742-53. PMC: 1698896. DOI: 10.1038/sj.emboj.7601450. View

Yin T, Cook D, Lawrence M . ggbio: an R package for extending the grammar of graphics for genomic data. Genome Biol. 2012; 13(8):R77. PMC: 4053745. DOI: 10.1186/gb-2012-13-8-r77. View

Leggett D, Hanna J, Borodovsky A, Crosas B, Schmidt M, Baker R . Multiple associated proteins regulate proteasome structure and function. Mol Cell. 2002; 10(3):495-507. DOI: 10.1016/s1097-2765(02)00638-x. View

Niculescu 3rd A, Chen X, Smeets M, Hengst L, Prives C, Reed S . Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998; 18(1):629-43. PMC: 121530. DOI: 10.1128/MCB.18.1.629. View

Chen X, Randles L, Shi K, Tarasov S, Aihara H, Walters K . Structures of Rpn1 T1:Rad23 and hRpn13:hPLIC2 Reveal Distinct Binding Mechanisms between Substrate Receptors and Shuttle Factors of the Proteasome. Structure. 2016; 24(8):1257-1270. PMC: 4972676. DOI: 10.1016/j.str.2016.05.018. View

10.

Anchoori R, Jiang R, Peng S, Soong R, Algethami A, Rudek M . Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer. ACS Omega. 2018; 3(9):11917-11929. PMC: 6166221. DOI: 10.1021/acsomega.8b01479. View

11.

Zeng Y, El-Deiry W . Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene. 1996; 12(7):1557-64. View

12.

Suzuki Y, Nakabayashi Y, Takahashi R . Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci U S A. 2001; 98(15):8662-7. PMC: 37492. DOI: 10.1073/pnas.161506698. View

13.

Anchoori R, Karanam B, Peng S, Wang J, Jiang R, Tanno T . A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. 2013; 24(6):791-805. PMC: 3881268. DOI: 10.1016/j.ccr.2013.11.001. View

14.

Finley D, Chen X, Walters K . Gates, Channels, and Switches: Elements of the Proteasome Machine. Trends Biochem Sci. 2015; 41(1):77-93. PMC: 4706478. DOI: 10.1016/j.tibs.2015.10.009. View

15.

Lasker K, Forster F, Bohn S, Walzthoeni T, Villa E, Unverdorben P . Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. Proc Natl Acad Sci U S A. 2012; 109(5):1380-7. PMC: 3277140. DOI: 10.1073/pnas.1120559109. View

16.

Elsasser S, Gali R, Schwickart M, Larsen C, Leggett D, Muller B . Proteasome subunit Rpn1 binds ubiquitin-like protein domains. Nat Cell Biol. 2002; 4(9):725-30. DOI: 10.1038/ncb845. View

17.

Lu X, Ebelle D, Matsuo H, Walters K . An Extended Conformation for K48 Ubiquitin Chains Revealed by the hRpn2:Rpn13:K48-Diubiquitin Structure. Structure. 2020; 28(5):495-506.e3. PMC: 7205571. DOI: 10.1016/j.str.2020.02.007. View

18.

Greene E, Dong K, Martin A . Understanding the 26S proteasome molecular machine from a structural and conformational dynamics perspective. Curr Opin Struct Biol. 2019; 61:33-41. PMC: 7156321. DOI: 10.1016/j.sbi.2019.10.004. View

19.

Trader D, Simanski S, Kodadek T . A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells. J Am Chem Soc. 2015; 137(19):6312-9. PMC: 4455945. DOI: 10.1021/jacs.5b02069. View

20.

Cundiff M, Hurley C, Wong J, Boscia 4th J, Bashyal A, Rosenberg J . Ubiquitin receptors are required for substrate-mediated activation of the proteasome's unfolding ability. Sci Rep. 2019; 9(1):14506. PMC: 6787058. DOI: 10.1038/s41598-019-50857-y. View